Previous 10 | Next 10 |
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Art...
Salarius Pharmaceuticals, Inc. (SLRX) Q1 2022 Earnings Conference Call May 12, 2022, 05:00 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Arthur - Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Devel...
Salarius Pharmaceuticals press release (NASDAQ:SLRX): Q1 GAAP EPS of -$0.13 misses by $0.04. Co recorded no revenue for Q1 vs. revenue of $1.3M last year. As of March 31, 2022, total cash, cash equivalents, and restricted cash were $24.2 million, compared to $36.6 million as of March 31, 2021...
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein inhibition, a clinical-stage reversible LSD1 inhibitor Multiple potential de...
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, hematologic cancers and other cancers, today announced the successful com...
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webc...
Salarius Pharmaceuticals (NASDAQ:SLRX) shares dipped ~28% Friday morning after the biopharmaceutical company announced a $2.3M securities offering. The firm entered into definitive agreements with several institutional investors for the purchase of 9,339,436 shares of its common sto...
HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that it has entered into definitive agreements with several instit...
Salarius Pharmaceuticals, Inc. (SLRX) Q4 2021 Earnings Conference Call March 10, 2022 17:00 ET Company Participants Jason Rando - Investor Relations David Arthur - Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Danie...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NYSE Market:
Salarius Pharmaceuticals Inc. Website:
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...